Increasing LV and AAV Titers to Meet Cell & Gene Therapy Needs
Email alerts
Free registration
Chat area
Certificate of attendance
Gene therapies show great promise for treatment of disease, and transient transfection is a critical component for enabling the high titer and large-scale viral vector manufacturing processes that support these therapies. We showcase a transfection solution and parameters intended to increae LV and AAV yields while decreasing costs through the use of less resources such as DNA and labor.
In this webinar, we outline the need for increasing manufacturing efficiency to generate sufficient doses for large patient populations and introduce the TransIT-VirusGEN® Transfection Reagent and upcoming LV and AAV Enhancers along with critical parameters to meet this need in order to support cell and gene therapies.
Presented by
Leisha Kopp
Leisha Kopp is an Applications Scientist at Mirus Bio LLC, a biotech company providing innovative transfection products to cell culture researchers worldwide. Leisha has over 15 years of molecular biology and mammalian cell culture experience in industrial labs, which enables her to support of scientists in all stages of the drug discovery process - from R&D to commercial manufacturing. Leisha is a graduate of the University of Wisconsin-Madison, with key interests in biotherapeutic antibody discovery and gene therapy.